PULsecath mechanicaL Support Evaluation



Status:Enrolling by invitation
Conditions:Peripheral Vascular Disease, Cardiology, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:2/14/2018
Start Date:December 2016
End Date:December 2018

Use our guide to learn which trials are right for you!

PULsecath mechanicaL Support Evaluation (PULSE) - Trial

The objective of this study is to determine ventricular loading conditions during and after
PulseCath® iVAC2L support, and assess its impact on specific load dependent humoral factors
and cardiac enzymes. These specific patterns are so far unknown and will be compared with the
validated FDA-cleared and CE marked Impella CP. Ten cases with Impella CP will be performed
in this study to obtain the exact same measurements for comparing purposes.

This is a mechanistic exploratory study. The objective is to determine the effects of the new
PFLVAD PulseCath® iVAC2L and the CFLVAD Impella CP on ventricular loading using left
ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic
parameters obtained from right and left catheterization. Additionally, assessments of
specific load and flow-dependent humoral factors and cardiac enzymes will be made during and
after the use of mechanical circulatory support. These specific patterns are so far unknown
and will be compared with the LV-to-arterial continuous flow CFLVAD Impella CP. Ten cases
treated with Impella CP will be included in this study to obtain the exact same variables for
comparing purposes. Knowledge of optimal patterns may help in determining the ideal
circulatory device platform. If a difference is demonstrated, a randomized trial could be
designed to detect differences in clinical outcomes between pulsatile and continuous flow
circulatory support.

Inclusion Criteria:

1. Patient is ≥ 18 years;

2. Informed Consent must be signed by the patient, prior to HR-PCI;

3. The multidisciplinary heart team has reached consensus for high-risk PCI. Patients may
present with left ventricular systolic dysfunction (ejection fraction ≤40%);

4. Anatomical criteria: Intervention to an unprotected left main coronary artery, left
main equivalent or single remaining vessel; multivessel disease; intervention in a
distal left main bifurcation.

Exclusion Criteria:

1. No written informed consent;

2. Left ventricular thrombus;

3. Interventricular septal defect;

4. Significant peripheral arterial disease or arterial lumen size < 6mm at the level of
the common femoral artery;

5. Significant aortic valve disease (more than mild aortic stenosis/regurgitation);

6. Cardiogenic shock;

7. Previous stroke within the last 3 months;

8. Major bleeding event within last 3 months;

9. Chronic kidney disease with a GFR < 25 mL/min;
We found this trial at
2
sites
Toulouse, 31300
?
mi
from
Toulouse,
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials